COMPANY RESEARCH PROFILE · UPDATED 2026-09-29

Akeso

Commercial-stage biopharmaceutical company developing bispecific antibodies and other biologics, including ivonescimab, which is partnered with Summit Therapeutics across major markets outside Akeso's retained territories.

TICKER9926.HK

HEADQUARTERSZhongshan, China

STAGEApproved

ACTIVE TRIALS84

Therapeutic areas

OncologyImmunology

Selected products and programs

ivonescimabcadonilimab

Linked curated drug profiles

cadonilimab

PD-1/CTLA-4 bispecific antibody

ivonescimab

PD-1/VEGF bispecific antibody

Selected active clinical trials

A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

Phase 3 · Recruiting · Hepatocellular Carcinoma

A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection

Phase 3 · Recruiting · Hepatocellular Carcinoma

A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC

Phase 3 · Recruiting · NSCLC (Non-small Cell Lung Cancer)

A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

Phase 3 · Recruiting · Gastric and Gastroesophageal Junction Adenocarcinoma

AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer

Phase 3 · Recruiting · Triple-Negative Breast Cancer (TNBC)

A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Phase 3 · Recruiting · Head and Neck Squamous Cell Carcinoma

Selected patent records

No linked FDA Orange Book patent record was found for the selected products.

Primary and company sources

Company and pipeline information can change. Verify material decisions against the linked primary sources.

Evidence & limits

Source: Open the source record

Record identifier: /companies/akeso/
Event / action date: Not separately retained
Source update date: Not separately retained
Platform retrieval / processing date: Not separately retained

What it supports. Connections found through the catalog, identifiers, or name and alias matching, with source links where retained.

Limits. A company association is not proof of ownership or sponsorship of every linked record. Product, substance, parent-company, and subsidiary relationships may differ.

Connection basis. Catalog, identifier, or normalized name association. Product and company connections are research leads, not ownership determinations.

What this record means · Report an issue with this record